Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Sangamo Therapeutics fourth quarter and full year 2024 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today. Please go ahead. Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie Dubar-Stringfellow, Chief Development Officer, and Pratisha Durrababu, Chief Financial Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, Statements related to Sangamo's cash runway, plans to obtain additional capital and ability to continue operating as a going concern. The therapeutic and commercial potential and value of Sangamo's product candidates and technologies. Sangamo's ability to earn and receive payments from its collaboration and license agreements. Sangamo's expectations regarding new collaborations and license agreements. the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions, regulatory approvals, upcoming catalysts and milestones, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filing for the SEC, specifically in our annual report on Form 10-K. The fiscal year ended December 31, 2024. and subseq...